Vireo Growth (VREOF) Non-Current Debt (2020 - 2026)
Vireo Growth (VREOF) reported Non-Current Debt of $197.3 million for Q1 2026, up 215.16% on a YoY basis from $62.6 million in Q1 2025, and up 54.62% sequentially from $127.6 million in Q4 2025.
Vireo Growth (VREOF) Non-Current Debt (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Non-Current Debt data on file, last reported at $197.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt rose 215.16% year-over-year to $197.3 million; the trailing twelve-month figure through Mar 2026 stood at $197.3 million (up 215.16% YoY), and the FY2025 full-year result was $127.6 million, up 104.82% from the prior year.
- Non-Current Debt climbed to $197.3 million in Q1 2026, from $127.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $197.3 million in Q1 2026 to a low of $1.1 million in Q2 2024.
- A 5-year average of $63.6 million and a median of $56.0 million in 2023 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt sank 91.82% in 2023 and surged 7232.02% in 2025, its largest moves.
- Tracing VREOF's Non-Current Debt over 5 years: stood at $46.2 million in 2022, then jumped by 30.21% to $60.2 million in 2023, then gained by 3.45% to $62.3 million in 2024, then jumped by 104.82% to $127.6 million in 2025, then surged by 54.62% to $197.3 million in 2026.
- Business Quant data shows VREOF's Non-Current Debt at $197.3 million in Q1 2026, $127.6 million in Q4 2025, and $131.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 197.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.30 Mn |
| Dec 31, 2025 | 127.60 Mn |
| Sep 30, 2025 | 131.67 Mn |
| Jun 30, 2025 | 82.21 Mn |
| Mar 31, 2025 | 62.60 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | 56.83 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 60.22 Mn |
| Sep 30, 2023 | 4.06 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 55.16 Mn |
| Dec 31, 2022 | 46.25 Mn |
| Sep 30, 2022 | 49.61 Mn |
| Jun 30, 2022 | 45.85 Mn |
| Mar 31, 2022 | 31.21 Mn |
| Dec 31, 2021 | 27.33 Mn |
| Sep 30, 2021 | 20.52 Mn |
| Jun 30, 2021 | 18.53 Mn |
| Mar 31, 2021 | 17.65 Mn |